Literature DB >> 11499807

Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector.

B E Power1, J M Caine, J E Burns, D R Shapira, M K Hattarki, K Tahtis, F T Lee, F E Smyth, A M Scott, A A Kortt, P J Hudson.   

Abstract

A single-chain antibody fragment (scFv) of the humanised monoclonal antibody, hu3S193, that reacts specifically with Le(y) antigen expressed in numerous human epithelial carcinomas was constructed. A five-residue linker joined the C-terminus of the V(H) and the N-terminus of the V(L), which prevented V-domain association into a monomeric scFv and instead directed non-covalent association of two scFvs into a dimer or diabody. The diabody was secreted into the E. coli periplasm using a heat-inducible vector, pPOW3, and recovered as a soluble, correctly processed protein, following osmotic shock or solubilised with 4 M urea from the insoluble fraction. The diabody from both fractions was isolated by a rapid batch affinity chromatography procedure, using the FLAG affinity tag to minimise degradation and aggregation. The purified diabody has an Mr of approximately 54 kDa, was stable and demonstrated similar binding activity as the parent monoclonal antibody, as measured by FACS and BIAcore analyses. The radiolabelled diabody showed a rapid tumour uptake, with fast blood clearance, proving it to be an excellent potential candidate as a tumour-imaging agent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499807     DOI: 10.1007/s002620100192

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

1.  Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

Authors:  Barbara E Power; Larissa Doughty; Deborah R Shapira; John E Burns; Ann M Bayly; Joanne M Caine; Zhanqi Liu; Andrew M Scott; Peter J Hudson; Alexander A Kortt
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

3.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Authors:  Jennifer A Westwood; Mark J Smyth; Michele W L Teng; Maria Moeller; Joseph A Trapani; Andrew M Scott; Fiona E Smyth; Glenn A Cartwright; Barbara E Power; Dirk Hönemann; H Miles Prince; Phillip K Darcy; Michael H Kershaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  Construction, expression and tumor targeting of a single-chain Fv against human colorectal carcinoma.

Authors:  Jin Fang; Hong-Bin Jin; Jin-Dan Song
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

5.  Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.

Authors:  Jeffrey V Leyton; Tove Olafsen; Mark A Sherman; Karl B Bauer; Patrick Aghajanian; Robert E Reiter; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2008-10-28       Impact factor: 1.650

6.  Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.

Authors:  Matthew K Robinson; Calvin Shaller; Kayhan Garmestani; Paul S Plascjak; Kathryn M Hodge; Qing-An Yuan; James D Marks; Thomas A Waldmann; Martin W Brechbiel; Gregory P Adams
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

7.  Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas.

Authors:  D-J Kim; J-H Chung; Y-S Ryu; J-H Rhim; C-W Kim; Y Suh; H-K Chung
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.